Oxidative stress and antioxidant status in primary bone and soft tissue sarcoma by Nathan, F.M. et al.
RESEARCH ARTICLE Open Access
Oxidative stress and antioxidant status in primary
bone and soft tissue sarcoma
Fatima M Nathan1*, Vivek A Singh2, Amreeta Dhanoa1 and Uma D Palanisamy1
Abstract
Background: Oxidative stress is characterised by an increased level of reactive oxygen species (ROS) that disrupts
the intracellular reduction-oxidation (redox) balance and has been implicated in various diseases including cancer.
Malignant tumors of connective tissue or sarcomas account for approximately 1% of all cancer diagnoses in adults
and around 15% of paediatric malignancies per annum. There exists no information on the alterations of oxidant/
antioxidant status of sarcoma patients in literature. This study was aimed to determine the levels of oxidative stress
and antioxidant defence in patients with primary bone and soft tissue sarcoma and to investigate if there exists
any significant differences in these levels between both the sarcomas.
Methods: The study cohort consisted of 94 subjects; 20 soft tissue sarcoma, 27 primary bone sarcoma and 47
healthy controls. Malondialdehyde (MDA) and protein carbonyls were determined to assess their oxidative stress
levels while antioxidant status was evaluated using catalase (CAT), superoxide dismutase (SOD), thiols and trolox
equivalent antioxidant capacity (TEAC).
Results: Sarcoma patients showed significant increase in plasma and urinary MDA and serum protein carbonyl
levels (p < 0.05) while significant decreases were noted in TEAC, thiols, CAT and SOD levels (p < 0.05). No
significant difference in oxidative damage was noted between both the sarcomas (p > 0.05).
Conclusions: In conclusion, an increase in oxidative stress and decrease in antioxidant status is observed in both
primary bone and soft tissue sarcomas with a similar extent of damage. This study offers the basis for further work
on whether the manipulation of redox balance in patients with sarcoma represents a useful approach in the
design of future therapies for bone disease.
Background
Sarcomas are malignant connective tissue tumours and
can be classified into bone and soft tissue. While bone
sarcoma tumours arise from the skeleton, soft tissue sar-
comas are tumours of mesenchymal tissue such as blood
vessels, fat and muscle [1]. Although soft tissue sarco-
mas account for less than 1% of malignant neoplasms,
while bone sarcomas happen at a rate of one third of
their soft tissue counterparts, a vast majority of these
patients who develop these tumours eventually die from
metastatic diseases [2].
Various factors contribute to the development of sar-
comas that include environmental factors such as radia-
tion, viral infection and chemical exposure. Heritable
conditions also contribute to the occurrence of these
tumours that include Li-Fraumeni syndrome, retinoblas-
toma and Werner’s syndrome among others [3]. Various
evidences exist supporting the role of oxidants in the
development of cancers [4-6]. In bone tissues, recent
studies have demonstrated ROS generation as a key
modulator of bone cell function and that the pathophy-
siology of mineralised tissues is influenced by oxidative
stress [5]. However, apart from the known risk factors,
the function of oxidative stress in primary bone and soft
tissue sarcomas remain to be explored further.
Reactive oxygen species (ROS) not only present as
beneficial substances such as in chemotherapy and can-
cer apoptosis [3,4], but have also proven their role in
carcinogenesis [3,7]. They are either formed via enzy-
matic reactions (respiratory chain, cytochrome P450 sys-
tem and phagocytosis), or through non-enzymatic
reactions such as those offset by ionising radiation and
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those involving oxygen with organic compounds [7].
The balance of ROS as a beneficial substance is accom-
plished by the antioxidant defence system that is com-
posed of enzymatic (superoxide dismutase, SOD;
glutathione peroxidase, GPx; glutathione reductase, GRx
and catalase, CAT) and non-enzymatic (glutathione,
GSH and coenzyme Q10, CoQ10) [4].
The imbalance between the pro-oxidants and antioxi-
dants in favour towards the former gives rise to oxidative
stress that has been proven to lead to carcinogenesis
[4-6,8]. Increased ROS formation and decreased effi-
ciency of the antioxidant defence not only causes the per-
manent alteration of biomolecular structures (DNA,
proteins, lipids) but also their functions [4]. The damage
done to these molecules are assessed based on the idea
that although short-lived, ROS leave modified oxidative
products hence, the presence of biomarkers. The autoca-
talytic process of oxidative destruction to polyunsatu-
rated fatty acids (PUFA) caused by hydroxyl radicals and
oxygen generates markers of lipid damage such as 4-
hydroxynonenal (4-HNE) and malondialdehyde (MDA)
[9]. Protein functions are altered via backbone fragmen-
tation, side chain group oxidation, cross-linking and
unfolding among others that give rise to markers of pro-
tein oxidation in human studies [10]. In cancer, it has
been established that the higher the levels of oxidative
stress, the more extensive the cancer [4]. In a study on
paediatric acute lymphocytic leukaemia (ALL), children
who acquired higher antioxidant levels at the onset of
treatment had lesser complications and a better quality
of life [8]. To date, findings on antioxidant defence and
cancer imply that modifications to the antioxidant system
can result in the alteration of ROS removal [6-8].
Our study aims to determine the role of oxidative
stress in primary bone and soft tissue sarcoma patients
by assessing lipid and protein damage as well as enzy-
matic and non-enzymatic antioxidant levels. This would
provide a better understanding of the role of ROS in
sarcomas that could lead to the development of new
therapeutic strategies.
Methods
The study consisted of 47 consecutive patients with
bone and soft tissue sarcoma diagnosed at the Ortho-
paedic Oncology Unit, Department of Orthopaedics,
University Malaya Medical Centre between 1 June to 31
December, 2009. These patients ranged from ages 7 - 78
years (28 males and 19 females). The diagnosis of sarco-
mas was based on clinical, radiological and histopatholo-
gical findings. Representative samples of bone and soft
tissue tumors measuring 1 × 1 centimeter were taken
perioperatively during resection of tumour for histo-
pathological diagnosis. All the patients were newly diag-
nosed primary bone and soft tissue sarcoma cases. The
controls consisted of 47 healthy volunteers with ages
and social conditions similar to those of patients. Con-
sent was obtained from all patients and healthy indivi-
duals (controls) and the protocol had been approved by
the Medical Ethics Committee of University Malaya
Medical Centre (721.3/2009).
Sample Collection
Blood samples were collected from 27 patients with
bone sarcoma (ages 7 - 66 years) and 20 patients with
soft tissue sarcoma (ages 8 - 76 years). Five mililiters of
blood was collected from each patient; 1 mL for plain
tube, 3 mL for ethylene diaminetetraacetate (EDTA)
tube and 3 mL for citrated tube.
The blood collected in plain bottle without an anticoa-
gulant system was centrifuged at 5,000 rpm for 10 min-
utes, the precipitate discarded and the serum obtained
was utilised for protein carbonyl determination. Blood
collected using EDTA as the anticoagulant was centri-
fuged for 10 minutes at 5,000 rpm and the resulting
plasma was used in the determination of MDA, total
thiol, SOD, CAT activities and trolox equivalent antioxi-
dant capacity (TEAC). Urine obtained in urine specimen
containers was used for MDA measurement. Samples
acquired were stored at -80°C freezer until required for
analysis.
Measurement of Oxidative Damage
Determination of Lipid Peroxidation
Lipid peroxidation determination in plasma and urine
was based on the formation of malondialdehyde-thiobar-
bituric acid (MDA-TBA) adduct by the reaction between
MDA and TBA under acidic conditions at 100°C [11].
This was carried out using the Cayman’s Thiobarbituric
Acid Reactive Substances kit where absorbance of the
samples was measured at 532 nm using the Bio-Rad
Benchmark Plus Microplate Reader. The concentration
of MDA was determined using an MDA standard curve.
Normal human urine has a lipid peroxide level
(expressed in terms of MDA) of 0.8-2 μmol/g creatinine
[11]. Results were expressed as micromoles MDA per
litre plasma and micromoles MDA per gram of creati-
nine for urine samples.
Determination of Protein Carbonyl
Oxidative damage to proteins was determined in the
serum based on the formation of protein-hydrazone as a
result of the reaction between 2,4-dinitrophenylhydra-
zine (DNPH) and protein carbonyls [12] using the Cay-
man’s Protein Carbonyl Assay kit. Absorbance of the
samples was measured at 370 nm using the Bio-Rad
Benchmark Plus Microplate Reader. Carbonyl content
was determined using the extinction coefficient of
DNPH (0.022 μM-1cm-1). The total serum protein was
then measured at 280 nm using Levine’s method [13]
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on a LS-55 Fluorescence Spectrophotometer. Bovine
Serum Albumin (BSA) was used to construct a protein
standard curve. Protein carbonyl content in the serum
was then expressed as nanomoles per milligram protein.
Measurement of Antioxidant Status
Determination of Catalase Activity
The activity of catalase in the plasma using the CAT
peroxidatic ability for enzyme activity determination
where aliphatic alcohols function as specific CAT sub-
strates to form an aldehyde [14] was analysed using the
Cayman’s Catalase Assay kit. The formaldehyde formed
in the reaction between the enzyme and methanol in
the presence of optimal hydrogen peroxide concentra-
tion was measured calorimetrically with 4-amino-3-
hydrazino-5-mercapto-1,2,4-triazole (Purpald) [14]. The
absorbance was measured at 540 nm on the Bio-Rad
Benchmark Plus Microplate Reader and the reaction
rate was determined using the formaldehyde standard
curve. Results were expressed as unites per millilitre
plasma. One unit was defined as the amount of enzyme
causing the formation of 1.0 nmol formaldehyde per
minute at 25°C.
Determination of Superoxide Dismutase Activity
SOD activity was measured in the plasma based on a
tetrazolium salt to detect the formation of superoxide
radicals by xanthine and hypoxanthine [15] using the
Cayman’s Superoxide Dismutase Assay kit. The absor-
bance was measured at 450 nm using Bio-Rad Bench-
mark Plus Microplate Reader. The SOD activity was
measured using the linear regression equation from the
standard curve. Results were expressed as units per
millilitre plasma. One unit was defined as the amount of
enzyme required to exhibit 50% superoxide radical
dismutation.
Determination of Total Thiols
The determination of total thiols (T-SH) utilises an opti-
mised enzymatic recycling technique using 5,5’-dithio-
bis (2-nitrobenzoic acid) (DTNB) (CALBIOChem, USA)
[16]. 20 μL of the diluted plasma sample was added into
Eppendorf tubes followed by 400 μL methanol and 25
μL DTNB and the colour was left to develop for 20
minutes. The samples were then centrifuged at 3,000 ×
g for 10 minutes at 25°C. 90 μL was then loaded onto
the 96-well microplate and the absorbance was mea-
sured at 412 nm using the Bio-Rad Benchmark Plus
Microplate Reader. The T-SH concentration was calcu-
lated using the DTNB extinction coefficient (13.6 mM-
1cm-1). Results were expressed as micromoles per litre
plasma.
Determination of Trolox Equivalent Antioxidant Capacity
Plasma TEAC was determined by its ability to inhibit
peroxidase-mediated formation of the 2,2’-azino-bis-3-
ethylbenzthiozoline-6-sulfonate (ABTS.+) radical [17].
The capacity of the plasma antioxidant to inhibit ABTS
oxidation was compared to the water-soluble vitamin E
analogue (trolox) (Sigma-Aldrich Inc., USA). 20 μL of
diluted samples were loaded onto respective wells on
the 96-well microplate. 200 μL Chromagen (ABTS)
(Sigma-Aldrich Inc., USA) was then added to these
wells and the mixture left to react at 25°C for 6 minutes
before reading the absorbance at 750 nm using the Bio-
Rad Benchmark Plus Microplate Reader. The TEAC
values were determined from the trolox standard curve.
Results were expressed as millimoles per trolox equiva-
lents per litre plasma. TEAC values were taken as the
total antioxidant capacity in the plasma samples of the
patients.
Statistical Analysis
Triplicates of each sample were carried out in all of the
above assays. SPSS Version 16.0 for Windows (Chicago,
IL, USA) was used for data analysis. The significance of
difference between the patients and controls as well as
comparison between both sarcomas was determined
using the Mann-Whitney U test (median values) as the
data distribution was non-parametric. When data is
non-parametric, it is suggested that median rather mean
values be used. The independent t-test was used for
parametric distribution. Probability values of p < 0.05
were considered significant.
Results
Oxidative Damage
Oxidative damage to lipid and protein biomolecules in
the patients were measured by the level of lipid perox-
ides (MDA) formed in the plasma and the urine and
protein carbonyl in their serum. The median values are
as seen in Table 1.
Mann-Whitney U test showed that significantly higher
MDA levels were observed in the plasma and urine of
sarcoma patients as compared to the controls. When
measuring for protein damage, increase in protein car-
bonyl levels in the bone and soft tissue sarcoma patients
were observed compared to controls, with a p-value of
0.000 (p < 0.05). Our results indicate a significant
increase in both lipid and protein damage in patients
with primary bone and soft tissue sarcoma.
Antioxidant Status
The antioxidant status was assessed by studying the
levels of their non-enzymatic (TEAC and total thiol)
and enzymatic (SOD and CAT) antioxidants. Tables 2
and 3 show the median values of the respective para-
meters measured.
A lowered antioxidant defence system in sarcoma
patients compared to the respective controls was noted
(Table 2 and 3). TEAC was significantly lowered (53%)
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compared to the control group (p = 0.000, p < 0.05).
Total thiol concentration as well was drastically low-
ered (69%) compared to the control group (p < 0.05)
(Table 2).
It was also observed that the antioxidant enzymes,
SOD and CAT, were significantly reduced in patients
with bone and soft tissue sarcoma (p = 0.000) (Table 3).
Catalase activity was decreased in sarcoma patients by
43% in comparison to the control value. A 78% decrease
in SOD activity in sarcoma patients was observed as
compared to the control. It was evident that the antioxi-
dant enzymes (SOD and CAT) and non-enzymes (thiols
and TEAC) measured in this study were significantly
lowered in sarcoma patients compared to healthy
individuals.
Oxidative Damage in Bone and Soft Tissue Sarcoma
The extent of lipid and protein oxidation was compared
between both the sarcomas. Table 4 shows that there is
no significant difference between bone and soft tissue
sarcoma in plasma (p = 0.081) and urinary (p = 0.998)
MDA concentration and protein carbonyl levels (p =
0.085).
Antioxidant Status between Bone and Soft Tissue
Sarcoma
The antioxidant status based on the levels of enzymatic
antioxidants (SOD and CAT) and non-enzymatic anti-
oxidants (TEAC and thiols) in both sarcomas were com-
pared. TEAC concentrations in bone sarcoma were 5%
higher (0.62 ± 0.03) than those with soft tissue sarcoma
(0.59 ± 0.03), a difference which an independent t-test
showed no significance (p > 0.05) (Figure 1). Total thiol
concentration in bone (45.22 ± 1.26) was not signifi-
cantly different from soft tissue sarcoma (46.80 ± 1.36)
with a p-value of 0.406 (Figure 2).
Catalase activity in bone and soft tissue sarcoma
showed no significant difference (p = 0.146) (Figure 3).
A difference of 5.81% in SOD activity between bone and
soft tissue sarcoma patients was observed. This indicated
a non-significant difference (p > 0.05) between the sar-
comas. The mean SOD activities between both sarcomas
are as shown in Figure 4.
Discussion
This is the first study indicating the presence of oxida-
tive stress and diminished antioxidant status in bone
and soft tissue sarcoma. Free radicals attack lipids
mainly PUFA, giving rise to lipid peroxides that play a
pivotal role in cell division regulation [4]. The resulting
MDA formed from lipid peroxidation functions as a
tumour promoter and co-carcinogenic agent and has
the ability to hinder the role of antioxidant enzymes. A
direct correlation between lipid peroxidation and cell
proliferation with increased lipid damage in highly pro-
liferated cells has been noted [18]. In our study, urinary
MDA levels were more pronounced than plasma MDA
levels. While plasma MDA provides a picture of the
MDA levels in the circulation of patients at the particu-
lar time blood is drawn, urinary MDA levels depict
more of an end-product indicating the overall extent of
lipid peroxidation. The levels expressed in urine provide
a more accurate measure of lipid damage as aldehyde
activity in urine is more concentrated [19]. Oxidative
stress studies on various types of cancer have indicated
increased MDA levels as compared to normal indivi-
duals [4,6,8]. These findings correlate with the levels of
MDA measured in our study where a significant
increase was observed in sarcoma patients as compared
to healthy individuals.
Modifications to proteins are either elicited via direct
oxidative attack (on lysine or arginine) or as a secondary
reaction leading to the formation of protein carbonyls.
Table 1 Oxidative stress levels by measurement of plasma and urine MDA and protein carbonyl of bone and soft
tissue sarcoma patients and healthy individuals
Individuals n Plasma MDA (μmol/L) Urine MDA (μmol/g creatinine) Protein carbonyl
(nmol/mg protein)
Sarcoma Patients 47 7.30 ± 4.10 7.40 ± 10.90 0.79 ± 1.28
Healthy Individuals 47 2.40 ± 1.10 1.30 ± 0.70 0.37 ± 0.29
Values are median ± interquartile range
Table 2 Non-enzymatic plasma antioxidant status of
bone and soft tissue sarcoma patients and healthy
individuals
Individuals n TEAC (mM) Total SH (μmol/L)
Sarcoma Patients 47 0.64 ± 0.14 45 ± 8
Healthy Individuals 47 1.37 ± 0.06 144 ± 16
Values are median ± interquartile range
Table 3 Enzymatic antioxidant activity of plasma catalase
and SOD of bone and soft tissue sarcoma patients and
healthy individuals
Individuals n CAT activity (U/mL) SOD activity (U/mL)
Sarcoma Patients 47 15800 ± 2863 34 ± 34
Healthy Individuals 47 27800 ± 4314 154 ± 30
Values are median ± interquartile range
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However, studies are unable to differentiate between
those directly produced by protein oxidation and those
resulting from the addition of previously oxidised mole-
cules [20]. Protein carbonyls are more advantageous as
oxidative stress markers as oxidised proteins are gener-
ally more stable. They are produced in the circulation
earlier with an elevation observed for at least four hours
in the serum. Increased levels of protein carbonyl
groups have been observed in various diseases [4,6,8].
Nevertheless, there is limited documentation related to
protein oxidation in cancer [6]. The increase in protein
carbonyls not only reflects oxidative stress but also pro-
tein dysfunction caused by the disease [21]. Similar
observations were seen in our study where sarcoma
patients showed significantly increased protein carbonyl
levels as compared to the control group. Our findings of
increased MDA and protein carbonyls imply the occur-
rence of oxidative stress in sarcoma patients as a result
of lipid and protein damage.
The non-enzymatic antioxidant status (TEAC and
total SH) as well as the enzymatic antioxidant status
(CAT and SOD) was observed to have significantly
decreased in the sarcoma patients. The diminished levels
of antioxidant defence in the diseased individuals can be
accounted for by two theories. In the first, circulating
antioxidant reserves may have been exhausted in the
attempt to counteract the DNA, lipid and protein
damage. On another note, the elevated DNA, lipid and
protein oxidation may have occurred as a result of a
weakened defence system [22].
CAT functions in the conversion of hydrogen perox-
ide generated by a variety of reactions to water [23]. In
bones, hydrogen peroxide has been demonstrated to oxi-
dise proteins involved in cell differentiation and alter
their activity by either causing inhibition or stimulation
[5]. This suggests the possibility of hydrogen peroxide
being the main ROS in bone tumour development. The
possible raised levels of hydrogen peroxide may explain
the reduction in CAT observed in bone sarcoma
patients, in this study. Studies on colorectal cancer [6],
urothelial bladder carcinoma [22] and ovarian cancer
[24] have similarly demonstrated a decrease in both
CAT and SOD. A reduction in CAT may also be
accounted for by increased MDA forming cross-links
Table 4 Comparing oxidative damage in bone and soft tissue sarcoma by measuring plasma and urinary MDA and
protein carbonyl content
Sarcoma n Plasma MDAa
(μmol/L)
Urine MDAb
(μmol/g creatinine)
Protein Carbonyla (nmol/mg protein)
Bone 27 6.80 ± 3.10 9.50 ± 1.61 0.96 ± 2.02
Soft Tissue 20 8.20 ± 4.00 9.51 ± 1.39 0.71 ± 0.86
a Median ± interquartile range
bMean ± SE
Figure 1 TEAC concentration in bone and soft tissue sarcoma.
Figure 2 Total thiol status in bone and soft tissue sarcoma.
Bone (n = 27) and soft tissue (n = 20). Results represent mean ±
SEM. Independent t-test: no significant difference observed between
the groups (p > 0.05).
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hence, hindering the activity of membrane-bound
enzymes [24].
A decrease in SOD activity was also observed in the
sarcoma patients. Colorectal cancer [6] and other cancers
[22,24] have shown similar reductions in SOD activity.
When subjected to moderate levels of oxidative stress,
oxidation of cysteine residues has been found to cause
mixed disulphide formations between protein thiol
groups and low-molecular mass thiols (S-thiolation),
mainly with GSH (S-glutathionylation). Protein function
can be altered and regulated directly by protein S-glu-
tathionylation that may also function in defence against
irreversible oxidation. Under oxidative stress conditions
these proteins accumulate, although they are readily
reduced to free thiol groups when the normal redox bal-
ance is recovered by the glutaredoxins or reducing
agents. A decrease in ratio of glutathione (GSH):glu-
tathione disulphide (GSSG) (oxidised form:reduced
form) indicates the occurrence of diseased states [25].
GSH plays a role in detoxification and bioreduction pro-
cesses [4]. The decrease in thiol levels and enzymes
involved in maintaining these levels (GPx) has been impli-
cated in various types of cancer [4,22]. The decrease
observed in these levels may result from its depletion due
to the presence of increased hydrogen peroxide levels [4]. It
was identified that decreased GPx activity may be a result
of inactivation by the superoxide anion. With a reduction in
GPx, the conversion of hydrogen peroxide to water remains
incomplete [26]. GPx utilises GSH as a co-substrate in this
defence mechanism [9] implying that an increase in hydro-
gen peroxide would cause more GPx to combine with GSH
to produce GSSG. This process continues until the GPx
and GSH reserves are exhausted accounting for a decrease
in the total thiol levels. Our study on sarcoma patients
showed a reduction in the total thiol levels.
Trolox, a water-soluble derivative of vitamin E was
used to depict the antioxidant system [24]. It was shown
that vitamin E present with lipids in the cell membrane
inhibits cancer formation by neutralising ROS [4] and a
direct relationship has been established with vitamin E
deficiency and lipid peroxide production [27]. This evi-
dence supports our findings where a decrease in plasma
TEAC observed may be due to the increased lipid per-
oxidation observed. However, it should be noted that
the low levels of vitamin E observed in this study may
also be due to its hydrophobicity.
Sarcomas are defined as a type of cancerous connec-
tive tissue tumour [3]. As a result of different oxidative
loads in varying tissues, the total antioxidant capacity
varies. Individual tissues acquire their own antioxidant
composition based on the oxidising courses that it most
likely would endeavour [28]. Bone and soft tissue sarco-
mas arise from connective tissue [3], indicating the pos-
sibility that oxidising processes and antioxidant defence
mechanisms in these two sarcomas are similar.
Tumours arising in bone and soft tissues share common
characteristic features due not only to common mesenchy-
mal origin but also the anatomical surrounding. Majority
of bone sarcomas are bicompartmental during presenta-
tion, destroying the cortex and spreading directly into the
soft tissue counterpart. On the other hand, soft tissue sar-
comas are extracompartmental or found in an anatomical
region that is not blocked off by anatomical barriers.
Figures 3 Enzymatic antioxidant status (CAT activity) in bone
and soft tissue sarcoma.
Figure 4 Enzymatic antioxidant status (SOD activity) in bone
and soft tissue sarcoma. Bone (n = 27) and soft tissue (n = 20).
Results represent mean ± SEM. Independent t-test: no significant
difference between the groups (p > 0.05).
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These types of sarcomas extend only to adjacent compart-
ments at later stages of the disease [3]. Regardless of the
compartmentation, a clear link can be observed between
sarcomas in the bone and soft tissue suggesting that the
mechanism of oxidative damage and antioxidant defence
would most likely be similar. This would explain the rea-
son no significant difference in oxidative stress and antiox-
idant status in both sarcomas were observed.
Conclusions
To summarise, our studies for the first time on oxidative
stress and antioxidant status in both sarcomas clearly
indicated an increase in oxidative stress (enhanced lipid
and protein damage) and decrease in antioxidant status
(lowered SOD, CAT, thiols, TEAC). These findings cor-
roborate well with the oxidative stress and antioxidant
status of patients suffering from prostate [29], colorectal
[6] and ovarian [24] cancer. In addition, the similarities
in oxidative damage and antioxidant defence between
the bone and soft tissue sarcoma’s suggests a possible
link in the oxidising processes and antioxidant defence
mechanisms in these two sarcomas. It is however noted
that a larger cohort will provide a more significant result
on age, gender and racial distribution in the individual
types of bone and soft tissue sarcoma.
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